CDR-Life
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. Approach: Contrary to the classical cell surface targets, there is a reservoir of highly tumor-specific proteins inside the cancer cells. CDR-Life has developed a technology to make MHC-specific antibodies that target these highly tumor-specific intracellular antigens. Combined with our proprietary modular multispecific format, this enables us to develop tumor-selective & drug-like T cell engagers. Therapies: With access to a reservoir of unexploited intracellular cancer targets, we are advancing a growing pipeline of highly tumor-selective immunotherapies.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical / Health Care - Clinical Services
- Market Focus:
- Nationally (across the country)